Mason Freeman

This profile gathers the share dealings of Mason Freeman in CinCor Pharma, Inc., where the filings describe the role as chief executive. The record holds 3 filings, for trades running from 11 January 2022 to 26 January 2023.

The open-market side counts 1 purchase for €35k alongside 1 sale for €86. The net balance comes to €35k on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant. So far in 2023, the count stands at no purchases and 1 sale.

Most recently, on 27 February 2023, the filings show an open-market sale worth €86 in CinCor Pharma, Inc. The last insider purchase was made public on 13 January 2022, 1,739 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.